Evidence map›Paper›PMID 25922663›Full record

ArticleVascular cell2015

Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients.

Damien Vitiello, Diana Chaar, Paul-Eduard Neagoe, Anique Ducharme, Michel Carrier, Guy B Pelletier, Normand Racine, Mark Liszkowski, Martin G Sirois, Michel White

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Damien VitielloResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Diana ChaarResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Paul-Eduard NeagoeResearch Center, Montreal Heart Institute, Montréal, Qc Canada.
Anique DucharmeResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Michel CarrierResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Guy B PelletierResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Normand RacineResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Mark LiszkowskiResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Martin G SiroisResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.
Michel WhiteResearch Center, Montreal Heart Institute, Montréal, Qc Canada ; Université de Montréal, 5000 Belanger Street, Montreal, QC Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular endothelial growth factor (VEGF) may play a role on the allograft remodelling following cardiac transplantation (CTx). We measured the circulating levels of VEGF-A165 concomitantly with the proinflammatory (Interleukin-8; IL-8), anti-inflammatory (IL-1 receptor antagonist; IL-1RA) and their release from neutrophils of CTx recipients.

methodsEighteen CTx recipients aged 49.6 ± 3.1 years, being transplanted for 145 ± 20 months were age-matched to 35 healthy control (HC) subjects. Concomitantly to plasma assessment, circulating neutrophils were isolated, purified and stimulated by vehicle (PBS), N-formyl-Met-Leu-Phe (fMLP, 10(-7) M), bacterial lipopolysaccharide (LPS, 1 μg/mL), or tumour necrosis factor alpha (TNF-α, 10 ng/mL).

resultsCompared with HC, CTx recipients exhibited a decrease (-80%) in plasmatic levels of VEGF-A165 (225 ± 42 (HC) vs 44 ± 10 pg/mL (CTx); (p < 0.001). There were no differences in the levels of IL-8 and IL-1RA. Under basal or stimulated conditions, neutrophils from CTx patients exhibited a marked decrease ranging from -30 to -88% on their capacity to release VEGF-A165, IL-8 and IL-1RA upon stimulation.

conclusionsLong-term CTx recipients exhibit a marked reduction in the circulating levels of VEGF-A165, as well as neutrophil-mediated release of VEGF-A165, IL-1RA and IL-8 compared to healthy volunteers. The mechanisms and physiological impacts of these findings deserve additional investigations.

Indexed as

AllograftCardiac transplantationInflammationInterleukin-1 recipient antagonistNeutrophilsVEGF-A165

Identifiers

PMID25922663
PMCPMC4411699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.